Literature DB >> 11154267

Multifaceted regulation of cell cycle progression by estrogen: regulation of Cdk inhibitors and Cdc25A independent of cyclin D1-Cdk4 function.

J S Foster1, D C Henley, A Bukovsky, P Seth, J Wimalasena.   

Abstract

Estrogens induce proliferation of estrogen receptor (ER)-positive MCF-7 breast cancer cells by stimulating G(1)/S transition associated with increased cyclin D1 expression, activation of cyclin-dependent kinases (Cdks), and phosphorylation of the retinoblastoma protein (pRb). We have utilized blockade of cyclin D1-Cdk4 complex formation through adenovirus-mediated expression of p16(INK4a) to demonstrate that estrogen regulates Cdk inhibitor expression and expression of the Cdk-activating phosphatase Cdc25A independent of cyclin D1-Cdk4 function and cell cycle progression. Expression of p16(INK4a) inhibited G(1)/S transition induced in MCF-7 cells by 17-beta-estradiol (E(2)) with associated inhibition of both Cdk4- and Cdk2-associated kinase activities. Inhibition of Cdk2 activity was associated with delayed removal of Cdk-inhibitory activity in early G(1) and decreased cyclin A expression. Cdk-inhibitory activity and expression of both p21(Cip1) and p27(Kip1) was decreased, however, in both control and p16(INK4a)-expressing cells 20 h after estrogen treatment. Expression of Cdc25A mRNA and protein was induced by E(2) in control and p16(INK4a)-expressing MCF-7 cells; however, functional activity of Cdc25A was inhibited in cells expressing p16(INK4a). Inhibition of Cdc25A activity in p16(INK4a)-expressing cells was associated with depressed Cdk2 activity and was reversed in vivo and in vitro by active Cdk2. Transfection of MCF-7 cells with a dominant-negative Cdk2 construct inhibited the E(2)-dependent activation of ectopic Cdc25A. Supporting a role for Cdc25A in estrogen action, antisense CDC25A oligonucleotides inhibited estrogen-induced Cdk2 activation and DNA synthesis. In addition, inactive cyclin E-Cdk2 complexes from p16(INK4a)-expressing, estrogen-treated cells were activated in vitro by treatment with recombinant Cdc25A and in vivo in cells overexpressing Cdc25A. The results demonstrate that functional association of cyclin D1-Cdk4 complexes is required for Cdk2 activation in MCF-7 cells and that Cdk2 activity is, in turn, required for the in vivo activation of Cdc25A. These studies establish Cdc25A as a growth-promoting target of estrogen action and further indicate that estrogens independently regulate multiple components of the cell cycle machinery, including expression of p21(Cip1) and p27(Kip1).

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11154267      PMCID: PMC86671          DOI: 10.1128/MCB.21.3.794-810.2001

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  103 in total

1.  Oestrogen-responsive human breast cancer in long term tissue culture.

Authors:  M E Lippman; G Bolan
Journal:  Nature       Date:  1975-08-14       Impact factor: 49.962

2.  Transcriptional regulation of c-myc oncogene expression by estrogen in hormone-responsive human breast cancer cells.

Authors:  D Dubik; R P Shiu
Journal:  J Biol Chem       Date:  1988-09-05       Impact factor: 5.157

Review 3.  The role of oestrogens and progestagens in the epidemiology and prevention of breast cancer.

Authors:  T J Key; M C Pike
Journal:  Eur J Cancer Clin Oncol       Date:  1988-01

4.  Stimulation of c-myc oncogene expression associated with estrogen-induced proliferation of human breast cancer cells.

Authors:  D Dubik; T C Dembinski; R P Shiu
Journal:  Cancer Res       Date:  1987-12-15       Impact factor: 12.701

5.  A new cellular model of response to estrogens: a bioluminescent test to characterize (anti) estrogen molecules.

Authors:  M Pons; D Gagne; J C Nicolas; M Mehtali
Journal:  Biotechniques       Date:  1990-10       Impact factor: 1.993

6.  Estrogen responsive proliferation of clonal human breast carcinoma cells in athymic mice.

Authors:  H D Soule; C M McGrath
Journal:  Cancer Lett       Date:  1980-08       Impact factor: 8.679

7.  Mode of estrogen action on cell proliferation in CAMA-1 cells: II. Sensitivity of G1 phase population.

Authors:  B S Leung; A H Potter
Journal:  J Cell Biochem       Date:  1987-07       Impact factor: 4.429

8.  Cell proliferation kinetics of MCF-7 human mammary carcinoma cells in culture and effects of tamoxifen on exponentially growing and plateau-phase cells.

Authors:  R L Sutherland; R E Hall; I W Taylor
Journal:  Cancer Res       Date:  1983-09       Impact factor: 12.701

9.  cdc25 is a specific tyrosine phosphatase that directly activates p34cdc2.

Authors:  J Gautier; M J Solomon; R N Booher; J F Bazan; M W Kirschner
Journal:  Cell       Date:  1991-10-04       Impact factor: 41.582

10.  Specific activation of cdc25 tyrosine phosphatases by B-type cyclins: evidence for multiple roles of mitotic cyclins.

Authors:  K Galaktionov; D Beach
Journal:  Cell       Date:  1991-12-20       Impact factor: 41.582

View more
  60 in total

1.  Transforming growth factor beta facilitates beta-TrCP-mediated degradation of Cdc25A in a Smad3-dependent manner.

Authors:  Dipankar Ray; Yasuhisa Terao; Dipali Nimbalkar; Li-Hao Chu; Maddalena Donzelli; Tateki Tsutsui; Xianghong Zou; Asish K Ghosh; John Varga; Giulio F Draetta; Hiroaki Kiyokawa
Journal:  Mol Cell Biol       Date:  2005-04       Impact factor: 4.272

2.  The cyclin D1 proto-oncogene is sequestered in the cytoplasm of mammalian cancer cell lines.

Authors:  John P Alao; Simon C Gamble; Alexandra V Stavropoulou; Karen M Pomeranz; Eric W-F Lam; R Charles Coombes; David M Vigushin
Journal:  Mol Cancer       Date:  2006-02-17       Impact factor: 27.401

3.  CARM1 is an important determinant of ERα-dependent breast cancer cell differentiation and proliferation in breast cancer cells.

Authors:  Mariam Al-Dhaheri; Jiacai Wu; Georgios P Skliris; Jun Li; Ken Higashimato; Yidan Wang; Kevin P White; Paul Lambert; Yuerong Zhu; Leigh Murphy; Wei Xu
Journal:  Cancer Res       Date:  2011-01-31       Impact factor: 12.701

4.  Estrogen regulation of cyclin E2 requires cyclin D1 but not c-Myc.

Authors:  C Elizabeth Caldon; C Marcelo Sergio; Judith Schütte; Marijke N Boersma; Robert L Sutherland; Jason S Carroll; Elizabeth A Musgrove
Journal:  Mol Cell Biol       Date:  2009-06-29       Impact factor: 4.272

5.  Increased risk of stroke in oral contraceptive users carried replicated genetic variants: a population-based case-control study in China.

Authors:  Chun Wang; Ying Li; Huiqiao Li; Tao Sun; Guangfu Jin; Zhiming Sun; Jian Zhou; Lei Ba; Zhizheng Huang; Jianling Bai
Journal:  Hum Genet       Date:  2012-04-04       Impact factor: 4.132

6.  Functional interactions between the estrogen receptor coactivator PELP1/MNAR and retinoblastoma protein.

Authors:  Seetharaman Balasenthil; Ratna K Vadlamudi
Journal:  J Biol Chem       Date:  2003-04-07       Impact factor: 5.157

7.  Stable inhibition of specific estrogen receptor α (ERα) phosphorylation confers increased growth, migration/invasion, and disruption of estradiol signaling in MCF-7 breast cancer cells.

Authors:  B P Huderson; T T Duplessis; C C Williams; H C Seger; C G Marsden; K J Pouey; S M Hill; B G Rowan
Journal:  Endocrinology       Date:  2012-06-25       Impact factor: 4.736

8.  Co-treatment of mouse antral follicles with 17β-estradiol interferes with mono-2-ethylhexyl phthalate (MEHP)-induced atresia and altered apoptosis gene expression.

Authors:  Zelieann R Craig; Jeffrey Singh; Rupesh K Gupta; Jodi A Flaws
Journal:  Reprod Toxicol       Date:  2014-01-09       Impact factor: 3.143

9.  17alpha-estradiol inhibits LAPC-4 prostatic tumor cell proliferation in cell cultures and tumor growth in xenograft animals.

Authors:  Yaming Qiao; Zhi-Kai Zhang; Li-Qun Cai; Chen Tan; Julianne L Imperato-McGinley; Yuan-Shan Zhu
Journal:  Prostate       Date:  2007-12-01       Impact factor: 4.104

Review 10.  Tailoring to RB: tumour suppressor status and therapeutic response.

Authors:  Erik S Knudsen; Karen E Knudsen
Journal:  Nat Rev Cancer       Date:  2008-09       Impact factor: 60.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.